The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.
Eslicarbazepine acetate (Zebinix®) has been rejected for use as an adjunctive therapy in adults with partial-onset seizures with or without secondary generalisation. The review notes that efficacy has been demonstrated in three 12-week placebo controlled trials but that no active comparator studies have been completed. The economic analysis in the submission was not sufficiently robust to gain acceptance.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« ACCORD analysis||MeReC Extra 43 »|